Skip to main content
PolicySpeak
← All files
EPT

European Paediatric Translational Research Infrastructure (EPTRI)

Academic / research · Belgium

not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts — staff, costs, accreditations — are not available for it.

2
positions filed
in the 583 files tracked
1
legislative file
of 583 tracked
2
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Track European in PolicySpeak: request access →

Work at European Paediatric Translational Research Infrastructure (EPTRI)? so we know who speaks for it.

Follow the file European Paediatric Translational Research Infrastructure (EPTRI) engages with

One email on Tuesdays when a new position is filed on this file, from European Paediatric Translational Research Infrastructure (EPTRI) or from anyone else on it. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

European Paediatric Translational Research Infrastructure (EPTRI) filed 2 positions between 16 Oct 2023 and 23 Oct 2023, across 1 of the 583 legislative files tracked here, attaching a full position paper 2 times.

What they argued

Medicinal products for human usefiled 23 Oct 2023PDFsource

Compared to adults, children face lack of effective treatments, increased adverse events due to off-label medication use, and limited access to appropriate medicines. Currently, only 35% of marketed drugs have been specifically developed and approved for paediatric use, leading to significant risks and challenges for this vulnerable population.

Medicinal products for human usefiled 16 Oct 2023PDFsource

Compared to adults, children face lack of effective treatments, increased adverse events due to off-label medication use, and limited access to appropriate medicines. Currently, only 35% of marketed drugs have been specifically developed and approved for paediatric use, leading to significant risks and challenges for this vulnerable population.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put European Paediatric Translational Research Infrastructure (EPTRI) next to another organization. Same files, same register facts, side by side. Compare →

Is this your organization?

Everything on this page comes from European Paediatric Translational Research Infrastructure (EPTRI)’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.